VANTAS SUMMARY
Vantas Implant
Vantas™ (histrelin implant) is a sterile non-biodegradable, diffusion-controlled reservoir drug delivery system designed to deliver histrelin continuously for 12 months upon subcutaneous implantation. The Vantas implant contains 50 mg of histrelin acetate. Histrelin acetate is a synthetic nonapeptide analogue of the naturally occurring gonadotropin releasing hormone (GnRH) or luteinizing hormone releasing hormone (LH-RH). The sterile Vantas implantation device (provided with the implant) is used to insert the implant subcutaneously in the inner aspect of the upper arm. After 12 months, the implant must be removed. At the time the implant is removed, another implant may be inserted to continue therapy.
Vantas is indicated in the palliative treatment of advanced prostate cancer .
|
NEWS HIGHLIGHTSMedia Articles Related to Vantas (Histrelin Implant)
Side Effects Of Radiation To Treat Prostate Cancer Reduced By Biodegradable Implant
Source: Medical Devices / Diagnostics News From Medical News Today [2013.06.13]
Several years ago, Virginia Commonwealth University Massey Cancer Center became the first center in the United States to test an Israeli-invented device designed to increase the space between the prostate and the rectum in prostate cancer patients undergoing radiation therapy...
Hybrid Molecular Imaging System As Good As PET/CT Gold Standard For Restaging Patients With Metastatic Prostate Cancer
Source: MRI / PET / Ultrasound News From Medical News Today [2013.06.13]
When prostate cancer makes a comeback, it becomes increasingly important to have exceptional imaging available to find all possible regions where cancer has spread to other parts of the body, or metastasized, in order to plan the best possible treatment...
Vegetable Fats Reduce Prostate Cancer Death Risk
Source: Cancer / Oncology News From Medical News Today [2013.06.11]
Prostate cancer patients who replace animal fats and some carbohydrates with vegetable fats have a lower risk of premature death, researchers from the University of California reported in JAMA Internal Medicine. In the United States alone, nearly 2.5 million men currently live with prostate cancer...
Tweaking Dietary Fat Mix Might Boost Prostate Cancer Survival
Source: MedicineNet Prostate Cancer Specialty [2013.06.11]
Title: Tweaking Dietary Fat Mix Might Boost Prostate Cancer Survival
Category: Health News
Created: 6/10/2013 4:36:00 PM
Last Editorial Review: 6/11/2013 12:00:00 AM
Heart-Healthy Diet May Be Prostate Cancer Healthy Too
Source: Medscape Family Medicine Headlines [2013.06.10]
Men with prostate cancer who eat nuts, skip bread, and enjoy salad dressing made of vegetable oils could possibly live longer.
Medscape Medical News
Published Studies Related to Vantas (Histrelin Implant)
Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. [2011.08.18]
Study Type - Therapy (individual cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Androgen deprivation therapy with a gonadotropin-releasing hormone agonist is an effective option for the palliative treatment of advanced prostate cancer. This study demonstrated the safety and efficacy of the histrelin acetate implant over successive one year treatment cycles for up to four years in an open-label extension trial. OBJECTIVE: * To evaluate the efficacy and tolerability of a once-yearly histrelin implant during an open-label extension of a pivotal study... CONCLUSIONS: * The once-yearly histrelin implant maintained testosterone suppression for repeated treatment cycles and was generally well tolerated. * The histrelin implant provides a clinically attractive option for long-term androgen deprivation therapy in patients with advanced prostate cancer seeking fewer office visits and repeated injections. (c) 2011 THE AUTHORS. BJU INTERNATIONAL (c) 2011 BJU INTERNATIONAL.
Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer. [2010.08]
CONCLUSION: The GnRH agonist histrelin successfully suppressed testosterone over the entire study period. This effect was measured across a number of different clinical definitions of PSA response and clinical risk. The GnRH agonist therefore offers an effective therapy option in hormone treatment of prostate cancer.
Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant. [2010.06]
BACKGROUND: Gonadotropin free alpha-subunit (FAS) levels paradoxically increase during GnRH agonist (GnRHa) treatment of central precocious puberty (CPP). The histrelin implant suppresses gonadotropins and estradiol (E(2)) levels for 1 yr, but effects on FAS have not been described. OBJECTIVES: We aimed to determine whether FAS levels remain elevated during treatment with the implant, to assess the dynamics of FAS after removal, and to ascertain the reliability of FAS for monitoring gonadotropin secretion... CONCLUSIONS: Compared to LH, FSH, and E(2), FAS responds more rapidly to implant removal and represents the most sensitive indicator of gonadotropin recovery after histrelin implant treatment.
Histrelin: in advanced prostate cancer. [2010.03.26]
Histrelin is a gonadotropin-releasing hormone agonist available in a diffusion-controlled reservoir drug delivery system for subcutaneous implantation. The subcutaneous histrelin implant provided sustained suppression of serum testosterone, luteinizing hormone (LH) and prostate-specific antigen levels for up to 1 year in patients with advanced prostate cancer in two phase II or III trials...
Drug-induced liver injury caused by the histrelin (Vantus) subcutaneous implant. [2010.01]
Drug-induced liver injury (DILI) is the leading cause of acute hepatic failure in the United States... The case of a patient with liver injury following a subcutaneous histrelin (Vantus) implant as therapy for advanced prostate cancer is presented.
Clinical Trials Related to Vantas (Histrelin Implant)
Prospective Multicentre Non-interventional Study of VANTAS� for the Treatment of Patients With Advanced Prostate Cancer [Recruiting]
The aim of this non-interventional (observational) study is to document, in collaboration
with established urologists in Scandinavia, experience gained from routine use of Vantas®
for the treatment of patients with advanced prostate cancer. In this observational study
particular attention will be directed to treatment duration, quality of life and patient and
physician acceptance of the medicinal product for long-term therapy. Patient-based
measurement parameters such as quality of life and degree of satisfaction will allow
registration of information that extends beyond the clinical parameters. The knowledge
gathered will enable patient acceptance of long-term therapy to be evaluated. Clinical
outcome will also be documented by measuring serum testosterone and prostate specific
antigen (PSA) levels.
|
